GlaxoSmithKline Forecast, price target & analysts
GlaxoSmithKline Target price 2025 - Analyst rating & recommendation
GlaxoSmithKline Classifications & Recommendation:
GlaxoSmithKline Price Target
| Target Price | GBP16.71 |
| Price | GBP15.16 |
| Potential |
10.21%
register free of charge
|
| Number of Estimates | 19 |
|
19 Analysts have issued a price target GlaxoSmithKline 2026 .
The average GlaxoSmithKline target price is GBP16.71.
This is
10.21%
register free of charge
GBP26.50
74.80%
register free of charge
GBP11.90
21.50%
register free of charge
|
|
| A rating was issued by 23 analysts: 7 Analysts recommend GlaxoSmithKline to buy, 12 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the GlaxoSmithKline stock has an average upside potential 2026 of
10.21%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion GBP | 31.38 | 32.71 |
| 3.46% | 4.25% | |
| EBITDA Margin | 26.18% | 34.90% |
| 14.52% | 33.33% | |
| Net Margin | 8.19% | 18.49% |
| 50.09% | 125.66% |
18 Analysts have issued a sales forecast GlaxoSmithKline 2025 . The average GlaxoSmithKline sales estimate is
This results in the following potential growth metrics:
14 Analysts have issued an GlaxoSmithKline EBITDA forecast 2025. The average GlaxoSmithKline EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 GlaxoSmithKline Analysts have issued a net profit forecast 2025. The average GlaxoSmithKline net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share GBP | 0.63 | 1.48 |
| 48.36% | 134.92% | |
| P/E | 10.23 | |
| EV/Sales | 2.27 |
10 Analysts have issued a GlaxoSmithKline forecast for earnings per share. The average GlaxoSmithKline <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the GlaxoSmithKline stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
GlaxoSmithKline...
Current GlaxoSmithKline Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Nov 29 2024 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Sep 10 2024 |
| Deutsche |
Locked
➜
Locked
|
Locked | Sep 03 2024 |
| Shore Capital |
Locked
➜
Locked
|
Locked | Aug 28 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Jan 07 2025 |
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Nov 29 2024 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Sep 10 2024 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Sep 03 2024 |
|
Locked
Shore Capital:
Locked
➜
Locked
|
Aug 28 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
